2.2. Patient selection

A total of 54 adult (age > 18 years) LT recipients were enrolled, excluding those with renal dysfunction (eGFR < 60 mL/min/1.73 m²). On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group (n = 23) and the SMOFlipid group (n = 31), respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.